NCT05898477Recruiting
Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis
Source: ClinicalTrials.gov · Last updated 22 Jan 2026
Brief summary (registry, in English)
The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 1 Jun 2023
- Start date
- 1 May 2023
- Primary completion date
- Jan 2028
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Childhood cancers
- NCT number
- NCT05898477
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 1 May 2023 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients developing HLH\> 1 month after lymphoma diagnosis (for aggressive lymphomas)
- Patients with incomplete treatment and response documentation
Who the study is looking for
- Patients with lymphoma that are fulfilling at least one of the following:
- Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\>3,900 U/mL and ferritin\>1,000 ng/mL)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.